Lars Fruergaard Jørgensen
Lars Fruergaard Jørgensen is the CEO of Novo Nordisk, a leading global healthcare company based in Denmark that specializes in diabetes care and hormone replacement therapies. Under his leadership, the company has focused on innovation and sustainability, driving advancements in diabetes medications and weight management solutions. Recently, he has been vocal about the challenges of high drug prices in the U.S., addressing issues related to pharmacy benefit managers and the pricing mechanisms that affect patient access to medications.
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| Canada | 1 | 4.00 | 0.07% | +0% | 38,005,238 | 27,782 | $1,700,000 | 1,243$ |
| Totals | 1 | 38,005,238 | 27,782 | $1,700,000 | 1,243$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
Australia:
Lars Fruergaard Jørgensen will step down as CEO of Novo Nordisk amid market challenges.
5
Denmark:
Lars Fruergaard Jørgensen was the director of Novo Nordisk for eight years and had been with the company for 34 years.
5
Denmark:
Lars Fruergaard Jørgensen was the director of Novo Nordisk for eight years and has been with the company for 34 years.
5
United Kingdom:
Lars Fruergaard Jørgensen has led the company since 2017, overseeing its rise to become the most valuable company in Europe after the launch of its flagship anti-obesity drugs.
5
Denmark:
Lars Fruergaard Jørgensen is stepping down as CEO of Novo Nordisk after a significant decline in the company's value.
5
Denmark:
Lars Fruergaard Jørgensen pointed out the high American list prices of Novo Nordisk's products during a hearing in the USA.
6
Denmark:
Lars Fruergaard Jørgensen highlighted the high list prices of Novo Nordisk's medications in the USA.
5